The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The role of MRD in CLL patients with high-risk cytogenetics & future perspectives
Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the importance of measurable residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL) who have high-risk cytogenetics, and further comments on where MRD may fit into clinical practice in the future and the need for more studies in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
